DENTSPLY SIRONA (XRAY) Insider Brian Mckeon Buys $101K of Stock
Brian McKeon acquired 10,000 shares of XRAY, valued at $101,200.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brian Mckeon bought 10,000 shares of DENTSPLY SIRONA Inc. ($XRAY) at an average price of $10.12, worth about $101,200, on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $XRAY is up 0.6% after 1 week, up 26.7% after 1 month and down 15.1% to date (from the $10.09 close on Jun 12, 2026).
XRAY
DENTSPLY SIRONA Inc.
Key Points
- Brian McKeon bought 10,000 shares of XRAY on June 12, 2026, at an average price of $10.12, totaling $101,200.
- Shares of XRAY traded at $10.36 with recent insider buying from multiple executives including Brian McKeon and Jonathan Jay Mazelsky.
- Analysts have mixed views on XRAY with Barclays maintaining a 'sell' rating and UBS a 'buy' rating, showing diverse opinions.
Get $XRAY trade alerts by text
We text you when insiders, Congress or big funds trade $XRAY. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated DENTSPLY SIRONA Inc. alert may contain errors. Disclosures
Brian McKeon, an insider at XRAY, purchased 10,000 shares of the company on June 12, 2026. The shares were bought at an average price of $10.12, making the total transaction worth approximately $101,200. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at DENTSPLY SIRONA Inc.
Several insiders at XRAY have been active in the market recently. Brian Gladden bought 9,985 shares on June 15 at $10.02 per share. On June 12, Jonathan Jay Mazelsky also acquired 10,000 shares at $10.14 each. Earlier, Betsy Holden and Michael Barber made purchases of 10,086 and 15,175 shares respectively at prices below $10 on June 11.
Analysts Set New Price Targets
Analyst opinions on XRAY are varied. On June 4, 2026, Barclays maintained a 'sell' rating with a price target of $9. Meanwhile, UBS continues to rate the stock as a 'buy' with a target price of $17, as of May 7, 2026. Citigroup initiated coverage with a 'sell' rating and a $10 target on April 15, 2026. The consensus among analysts is mixed, reflecting a range of expectations for XRAY's future performance.
Other Institutional Activity in XRAY
Institutional investors have also been active in XRAY. BlackRock, Inc. increased its holdings by 547,312 shares, now holding 19,251,869 shares valued at about $223.3 million. First Eagle Investment Management, LLC added 487,378 shares, bringing its total to 15,127,933 shares worth approximately $175.5 million. Fuller & Thaler Asset Management, Inc. grew its position by 287,008 shares to a total of 12,792,518 shares, valued at $148.4 million.
About XRAY
XRAY is a company operating in a sector not specified in the provided data. The company is involved in producing and distributing products or services, though specific details are not available in the current dataset. XRAY's headquarters, CEO, and employee count are not disclosed in the provided information.
Bottom Line
Brian McKeon's recent purchase of XRAY shares highlights insider confidence in the company. While insider transactions can indicate potential company performance insights, they are not definitive buy or sell signals. Analysts have mixed opinions on XRAY's outlook, reflecting diverse expectations within the market. As always, investors should consider multiple sources of information when evaluating stock performance.
Related Filing Alerts
Source: Brian Mckeon's Form 4 filing on $XRAY (Jun 12, 2026). Find the original filing: XRAY Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts